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Abstract
Background and Objective Chronic hepatitis C virus
(HCV) infection is a major cause of liver transplantation.
Drug–drug interactions (DDIs) with cyclosporine and
tacrolimus hindered the use of first-generation protease
inhibitors in transplant recipients. The current study in-
vestigated DDIs between daclatasvir—a pan-genotypic
HCV NS5A inhibitor with clinical efficacy in multiple
regimens (including all-oral)—and cyclosporine or tacro-
limus in healthy subjects.
Methods Healthy fasted subjects (aged 18–49 years;
body mass index 18–32 kg/m2) received single oral doses
of cyclosporine 400 mg on days 1 and 9, and daclatasvir
60 mg once daily on days 4–11 (group 1, n = 14), or a
single oral dose of tacrolimus 5 mg on days 1 and 13, and
daclatasvir 60 mg once daily on days 8–19 (group 2,
n = 14). Blood samples for pharmacokinetic analysis
[by liquid chromatography with tandem mass spectrometry
(LC–MS/MS)] were collected on days 1 and 9 for cy-
closporine (72 h), on days 1 and 13 for tacrolimus (168 h)
and on days 8 and 9 (group 1) or on days 12 and 13 (group 2)
for daclatasvir (24 h). Plasma concentrations were determined
by validated LC–MS/MS methods.
Results Daclatasvir did not affect the pharmacokinetic
parameters of cyclosporine or tacrolimus, and tacrolimus
did not affect the pharmacokinetic parameters of da-
clatasvir. Co-administration of cyclosporine resulted in a
40 % increase in the area under the concentration–time
curve of daclatasvir but did not affect its maximum ob-
served concentration.
Conclusion On the basis of these observations in healthy
subjects, no clinically relevant DDIs between daclatasvir
and cyclosporine or tacrolimus are anticipated in liver
transplant recipients infected with HCV; dose adjustments
during co-administration are unlikely to be required.
Key Points
Daclatasvir is a hepatitis C virus NS5A inhibitor
with potent pan-genotypic (genotypes 1–6) antiviral
activity in vitro.
Daclatasvir did not affect the pharmacokinetic
parameters of either cyclosporine or tacrolimus, and
tacrolimus did not affect the pharmacokinetic
parameters of daclatasvir.
Dose adjustments for daclatasvir, cyclosporine or
tacrolimus during co-administration are unlikely to
be required.
1 Introduction
Decompensated liver disease resulting from hepatitis C
virus (HCV) infection is a leading indication for liver
transplantation [1]. Furthermore, post-transplantation HCV
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recurrence is characterized by high levels of HCV repli-
cation and accelerated necro-inflammation and fibrosis,
significantly lower survival rates relative to those of non-
HCV infected transplant recipients, and limited treatment
options. Recurrence is ubiquitous if HCV infection is not
eradicated prior to liver transplantation [2, 3]. Although
pre-transplantation treatment with peginterferon/ribavirin
can prevent allograft re-infection if a sustained viral re-
sponse (SVR) is achieved, treatment is limited by poor
tolerability and low efficacy [4]. The low efficacy of this
regimen can be increased by the addition of first-generation
HCV protease inhibitors (boceprevir and telaprevir);
however, early discontinuation and hepatic decompensa-
tion rates complicate therapy with therapies that include
protease inhibitors [4]. It has also been shown that the
addition of the recently approved protease inhibitor
simeprevir [5, 6] and the NS5B inhibitor sofosbuvir [7, 8]
can improve viral response rates with peginterferon/
ribavirin to a greater degree than boceprevir or telaprevir,
and both are well tolerated when administered in con-
junction with peginterferon/ribavirin regimens.
In the post-transplantation setting, initiation and mainte-
nance of therapy with peginterferon/ribavirin in patients with
recurrent HCV is complicated by several factors, including
clinical characteristics that preclude full-dose therapy [9],
dose reductions (in 30–70 % of patients) and premature
discontinuations (in 20–40 % of patients) due to adverse
events (AEs) [9], low SVR rates (approximately 20 %)
[10] and interferon-related immune-mediated allograft
dysfunction [11].
Additionally, concomitant use of the current first-gen-
eration protease inhibitors in regimens for the treatment of
recurrent HCV in liver transplant recipients is complicated
by potentially severe drug–drug interactions (DDIs) with
immunosuppressants, such as the calcineurin inhibitors
cyclosporine and tacrolimus, for which there is a lifelong
requirement. The narrow therapeutic windows of both cy-
closporine and tacrolimus—coupled with the facts that
both are substrates of cytochrome P450 (CYP) 3A4 and
P-glycoprotein (P-gp) [12], and cyclosporine is also an
inhibitor of CYP3A4 and P-gp [13]—imply that careful
selection of concomitant therapies is required. For example,
telaprevir has been shown to cause significant increases in
the systemic exposures to both cyclosporine (4.6-fold) and
tacrolimus (70-fold) in healthy volunteers [14].
It is clear, therefore, that any direct-acting antiviral
agent that is to be used concomitantly with immunosup-
pressants such as cyclosporine and tacrolimus must have a
favourable pharmacokinetic DDI profile in addition to
good efficacy and tolerability. It has been shown that no
clinically relevant DDIs occur between cyclosporine or
tacrolimus and either simeprevir [15] or sofosbuvir [16].
Daclatasvir, a HCV NS5A inhibitor with potent pan-
genotypic (genotypes 1–6) antiviral activity in vitro [17], has
been evaluated in over 5500 patients in combinations with
other direct-acting antivirals and peginterferon/ribavirin
(data on file; study no. DACL-001). Daclatasvir has a
pharmacokinetic profile suitable for once-daily dosing
without food restrictions [18], is a substrate of both CYP3A4
[19] and P-gp, and has a low potential for clinically sig-
nificant DDIs [19–22]. Furthermore, concentrations of un-
bound daclatasvir are not affected to a clinically significant
level by moderate-to-severe hepatic impairment, and dose
adjustment is not required for this condition [23].
Only limited clinical data on the use of daclatasvir in
transplant recipients concomitantly taking calcineurin in-
hibitors are available at the current time. Daclatasvir has
been used successfully in combination with sofosbuvir as
part of a direct-acting antiviral-only regimen without signs
of a significant DDI with tacrolimus in a transplant re-
cipient with severe recurrent cholestatic HCV [24]. Da-
clatasvir has also been used successfully in combination
with peginterferon/ribavirin without signs of a significant
DDI with cyclosporine in a transplant recipient [25].
The aim of this study was to assess the effects of mul-
tiple doses of daclatasvir on the single-dose pharmacoki-




This was a phase 1, open-label, single-sequence, two-group
study in healthy subjects. The study consisted of a 28-day
screening period, a study treatment period and a health
status follow-up telephone contact at approximately 7 days
post-discharge.
Eligible subjects were admitted to the clinical research
facility on day -1 and were required to remain at the fa-
cility until discharge. The study duration for subjects in
group 1 was approximately 47 days, including the screen-
ing period, a 12-day study treatment period and the health
status follow-up; subjects in group 1 remained at the re-
search facility for a total of 12 days. The study duration for
subjects in group 2 was approximately 55 days, including
the screening period, a 20-day study treatment period and
the health status follow-up; subjects in group 2 remained at
the research facility for a total of 20 days.
Subjects in group 1 received a single oral dose of cy-
closporine 400 mg (Neoral; Novartis Pharmaceutical
Corporation, East Hanover, NJ, USA) on treatment days 1
and 9; daclatasvir 60 mg once daily (Daklinza; Bristol-
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Myers Squibb, Uxbridge, UK) was administered on days 4–11.
The treatment in group 2 consisted of a single oral dose of
tacrolimus 5 mg (Prograf; Astellas Pharma, Northbrook,
IL, USA) on treatment days 1 and 13; daclatasvir 60 mg once
daily was administered on days 8–19. The dosing schedules
differed between the two groups to allow for a wash-out
of either cyclosporine or tacrolimus prior to steady-state
daclatasvir dosing.
All subjects were required to fast for 10 h prior to
dosing; fasting continued until 4 h post-dose on days when
pharmacokinetic sampling (described below) and clinical
laboratory tests were performed (group 1, day 11; group 2,
day 19), and until 2 h post-dose on all other days. With the
exception of 240 mL of water ingested with dosing, sub-
jects refrained from drinking water from 1 h pre-dose until
1 h post-dose; water was consumed ad libitum at other
times. No concomitant medications (prescription, over-the-
counter or herbal) were administered during the study un-
less they were prescribed by the investigator for the treat-
ment of specific AEs.
This study was conducted in accordance with Good
Clinical Practice, as defined by the International Conference
on Harmonisation, and in accordance with the ethical prin-
ciples underlying European Union Directive 2001/20/EC
and the US Code of Federal Regulations (CFR), Title 21,
Part 50, at two clinical research facilities in the USA
(Omaha, NE, and San Antonio, TX) between 27 July 2012
and 16 October 2012. The protocol, protocol amendments
and written informed consent form were approved by an
Institutional Review Board (IntegReview, Austin, TX,
USA). Written informed consent was obtained from each
subject at the screening visit prior to the initiation of any
study-related procedures.
2.2 Study Population
The study population consisted of healthy (as determined
by a medical history, physical examination and measure-
ments, vital signs, clinical laboratory tests and 12-lead
electrocardiograms) male and female volunteers aged
19–49 years (inclusive) with a body mass index of
18–32 kg/m2 (inclusive) and a minimum body weight of
60 kg. Female subjects were not allowed to be nursing or
pregnant, and had to be using a highly effective method of
contraception for at least 1 month prior to dosing; addi-
tionally, a negative pregnancy test was required within
24 h prior to the initial dose of the investigational product.
2.3 Pharmacokinetic Sample Collection
Blood samples for the determination of cyclosporine
pharmacokinetics were collected on days 1 and 9 [at 0 h
(pre-dose) and at 0.5, 1, 1.5, 2, 4, 8, 12, 16, 24, 48 and
72 h post-dose]; samples for tacrolimus pharmacokinetic
analysis were collected on days 1 and 13 [at 0 h (pre-dose)
and at 0.5, 1, 1.5, 2, 3, 4, 8, 12, 16, 24, 48, 72, 96, 120, 144
and 168 h post-dose]. Cyclosporine and tacrolimus phar-
macokinetic sample collection times varied because of the
requirement for a wash-out prior to daclatasvir dosing and
differences in the half-life (t) values of cyclosporine and
tacrolimus.
Samples for the determination of daclatasvir pharma-
cokinetics were collected from pre-dose (at 0 h) to 0.5, 1,
1.5, 2, 4, 6, 8, 12, 16 and 24 h post-dose on days 8 and 9
(in group 1) and on days 12 and 13 (in group 2).
Approximately 288 mL of blood was drawn in total
from each subject in group 1 for pharmacokinetic analyses;
approximately 333 mL of blood was drawn from each
subject in group 2.
2.4 Pharmacokinetic Sample Analyses
Whole-blood concentrations of cyclosporine and tacroli-
mus were determined by previously validated liquid chro-
matography with tandem mass spectrometry (LC–MS/MS)
methods by Intertek Pharmaceutical Services (El Dorado
Hills, CA, USA) and PPD (Richmond, VA, USA), re-
spectively; daclatasvir plasma concentrations were deter-
mined using previously validated LC–MS/MS methods by
Tandem Labs (West Trenton, NJ, USA).
Cyclosporine and the internal standard (d4-CSP) were
extracted from human whole blood by liquid–liquid ex-
traction using methyl-t-butyl ether (MTBE). After evapora-
tion to dryness and reconstitution, the extracts were analysed
by reversed-phase LC–MS/MS coupled with atmospheric
pressure ionization (API). Tacrolimus was isolated by liq-
uid–liquid extraction using a mixture of ethyl acetate and
hexane. The solvent was evaporated under a nitrogen
stream. The final extract was analysed via high-performance
liquid chromatography (HPLC) with MS/MS detection.
Daclatasvir was extracted from plasma, using liquid–liquid
extraction by MTBE; all samples were evaporated under a
nitrogen stream. After drying and reconstitution, the extracts
were analysed by reversed-phase LC–MS/MS.
Cyclosporine, tacrolimus and daclatasvir chromatogra-
phy was performed on ACE 5 Phenyl (50 9 2.1 mm, 5 l),
Thermo Fisher Betasil C18 (2.1 mm 9 50 mm, 5 l) and
Fortis Phenyl (2.1 mm 9 50 mm, 5 l) columns,
respectively.
The mass analysers for cyclosporine and tacrolimus (API
4000; Applied Biosystems-MDS Sciex) and daclatasvir (API
4000 and API 5000; Applied Biosystems-MDS Sciex) were
operated in the positive polarity mode with mass transitions
of m/z 1220/1203, 821/768 and 370/130, respectively; the
corresponding limits of detection were 0.1–100, 0.25–100
and 2.0–2000 ng/mL, respectively.
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2.5 Safety Analyses
Safety assessments were based on a medical review of AE




Sample size calculations were based on the precision of
estimates and not statistical power concerns. It was con-
sidered that 14 subjects in each group were required to
ensure that at least 12 subjects in each group completed
treatment.
For the assessment of the effect of daclatasvir on cy-
closporine or tacrolimus pharmacokinetics, complete data
from 12 subjects would provide 90 % confidence intervals
(CIs) of the geometric mean ratio (GMR) point estimates of
the area under the concentration–time curve (AUC) from
time zero to infinite time (AUC?) and the maximum ob-
served concentration (Cmax) of 87–115 % and 86–117 %,
respectively, for cyclosporine, and 87–115 % and
79–127 %, respectively, for tacrolimus; complete data
from 12 subjects would provide 90 % CIs of the da-
clatasvir AUC? and Cmax GMRs of 91–110 % and
90–112 %, respectively.
2.6.2 Pharmacokinetic Analyses
The pharmacokinetic parameters of single-dose cy-
closporine and tacrolimus and multiple-dose daclatasvir
were derived from blood (cyclosporine and tacrolimus) and
plasma (daclatasvir) concentration–time data, using stan-
dard non-compartmental methods (WinNonlin Profes-
sional Network Edition, Version 5.2 or higher; Pharsight
Corporation, Sunnyvale, CA, USA).
The Cmax and the time to reach Cmax (Tmax) for single-
dose cyclosporine or tacrolimus and for multiple-dose da-
clatasvir were calculated and summarized by treatment.
Additional calculated pharmacokinetic parameters of cy-
closporine and tacrolimus included the AUC from time zero
to the time of the last quantifiable concentration (AUCT;
linear up/log down trapezoidal method), t and apparent
total body clearance (CLT/F). Additional pharmacokinetic
parameters of daclatasvir included the minimum observed
concentration at the end of the dosing interval (C24) and
AUC during one dosing interval (AUCtau).
The effects of daclatasvir on the pharmacokinetic pa-
rameters of cyclosporine and tacrolimus, and vice versa,
were assessed by the use of general linear mixed models
with fixed effects for treatment and measurements within
subject as repeated measures for log-transformed values of
Cmax and AUCT (of cyclosporine and tacrolimus), AUC?
(of cyclosporine and tacrolimus), AUCtau (of daclatasvir)
and C24 (of daclatasvir). Point estimates and 90 % CIs of
treatment differences on the log scale were exponentiated
to obtain estimates of the ratios of the geometric means on
the original scale. No adjustments for multiplicity were
made.
2.6.3 Safety Analyses
All recorded AEs, vital signs, clinical laboratory test results
and physical examination findings were listed, tabulated
and summarized by treatment group. AEs were categorized
by system organ class, preferred term [defined by the
Medical Dictionary for Regulatory Activities (MedDRA)],
severity and treatment relatedness.
3 Results
3.1 Subject Disposition and Baseline Demographic
Characteristics
A total of 98 subjects provided informed consent to be
screened for the study, and 28 subjects (28.6 %) were en-
rolled and received study medications. The reasons for
screened subjects not receiving study medication included
withdrawal of consent [n = 11 (11.2 %)], failure to meet
study entry criteria [n = 55 (56.1 %)] and other reasons
[n = 4 (4.1 %)].
All subjects received study medication per protocol,
completed the study and were included in both the phar-
macokinetic and safety evaluation populations. The base-
line demographic characteristics of subjects treated in both
treatment groups are presented in Table 1.





Age, years 34.8 (7.1) 34.5 (8.7)
Male, n (%) 12 (85.7) 10 (71.4)
Race, n (%)
White 6 (42.9) 10 (71.4)
Black/African American 7 (50.0) 4 (28.6)
Other 1 (7.1) 0
Body mass index, kg/m2 28.5 (2.7) 26.3 (3.7)
Values are expressed as mean (SD) unless specified otherwise
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3.2 Pharmacokinetics of Cyclosporine and Daclatasvir
Administered Alone and in Combination
The concentration–time profiles of single-dose cy-
closporine administered alone and in combination with
multiple-dose daclatasvir, and multiple-dose daclatasvir
administered alone and in combination with single-dose
cyclosporine, are presented in Fig. 1a, b, respectively.
The mean concentration–time profiles of single-dose
cyclosporine administered alone and in combination with
multiple-dose daclatasvir were nearly superimposable
(Fig. 1a). Individual measures of cyclosporine pharmacoki-
netic parameters (Table 2) when administered alone and in
combination with daclatasvir were comparable; cyclosporine
parameters showed moderate variability, and the elimination
was multiphasic. There was no effect of multiple-dose
administration of daclatasvir on the single-dose pharmacoki-
netics of cyclosporine; the 90 % CIs of the GMRs of Cmax,
AUCT and AUC? of cyclosporine when concomitantly
administered with daclatasvir versus administration alone
(Table 3) contained 1 and were contained entirely within the
accepted boundaries of equivalence (0.80 and 1.25).
Analyses of pre-dose and trough concentrations indi-
cated that steady-state pharmacokinetics of daclatasvir
were achieved within 3 days of dosing (data not shown).
When multiple-dose daclatasvir was co-administered with
single-dose cyclosporine, the mean peak plasma concen-
tration of daclatasvir was comparable to, but occurred later
than, that observed when daclatasvir was administered
alone; the rate of elimination appeared to be comparable
(Fig. 1b). The geometric mean of the daclatasvir Cmax
during co-administration with single-dose cyclosporine
was comparable to that when daclatasvir was administered
alone (Table 2); AUCtau, Tmax and C24 values during co-
administration were higher than those during administra-
tion of daclatasvir alone and demonstrated moderate vari-
ability. Co-administration with single-dose cyclosporine
did not significantly affect the Cmax of daclatasvir (the
90 % CIs of the GMR were contained within the equiva-
lence boundaries and included 1), although co-adminis-
tration with cyclosporine increased the daclatasvir AUCtau
(40 %) and C24 (56 %), with the 90 % CIs of the GMRs of
both AUCtau and C24 being entirely above the upper limit
of equivalence (1.25; Table 3).
Fig. 1 Concentration–time profiles of (a) cyclosporine (CSP) and (b) daclatasvir (DCV) administered alone and in combination, and
(c) tacrolimus (TAC) and (d) DCV administered alone and in combination. SD standard deviation
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3.3 Pharmacokinetics of Tacrolimus and Daclatasvir
Administered Alone and in Combination
The concentration–time profiles of single-dose tacrolimus
administered alone and in combination with multiple-dose
daclatasvir, and multiple-dose daclatasvir administered
alone and in combination with single-dose tacrolimus, are
presented in Fig. 1c, d, respectively.
The mean concentration–time profiles of single-dose
tacrolimus administered alone and in combination with
multiple-dose daclatasvir were comparable (Fig. 1c); the
elimination of tacrolimus was slow and multiphasic. The
individual measures of the tacrolimus pharmacokinetic
parameters (Table 2) when administered alone and in
combination with daclatasvir were comparable; the vari-
ability in tacrolimus pharmacokinetic parameters was
moderate. Concomitant multiple doses of daclatasvir did
not affect the single-dose pharmacokinetic of tacrolimus.
The 90 % CIs of the GMRs of Cmax, AUCT and AUC? of
tacrolimus when concomitantly administered with da-
clatasvir, versus administration alone (Table 3), contained
1 and were contained entirely within the accepted bound-
aries of equivalence.
As in group 1, analyses of pre-dose and trough con-
centrations indicated that steady-state pharmacokinetics
of daclatasvir were achieved within 3 days of dosing
Table 2 Pharmacokinetic parameters of daclatasvir administered alone and in combination with either cyclosporine or tacrolimus















CSP alone 1504 (20) 7825 (21) 8198 (21) ND ND 1.5 (1.0–2.0) 23.3 (3.3) 48.8 (23)
CSP ? DCV 1447 (20) 7989 (24) 8405 (24) ND ND 1.5 (1.0–2.0) 21.2 (5.4) 47.6 (25)
Group 1: DCV
DCV alone 1690 (31) ND ND 16,092 (32) 306 (44) 1.0 (1.0–4.0) ND ND
DCV ? CSP 1756 (25) ND ND 22,587 (24) 475 (30) 2.0 (1.5–4.0) ND ND
Group 2: TAC
TAC alone 22.8 (28) 225 (46) 246 (44) ND ND 1.5 (1.0–2.0) 40.4 (8.8) 20.3 (72)
TAC ? DCV 24.0 (40) 224 (59) 245 (56) ND ND 1.5 (0.6–2.0) 38.9 (6.5) 20.4 (76)
Group 2: DCV
DCV alone 1489 (20) ND ND 13,786 (28) 205 (43) 1.0 (1.0–1.5) ND ND
DCV ? TAC 1578 (27) ND ND 14,439 (30) 226 (33) 1.0 (0.6–1.5) ND ND
AUC area under the concentration–time curve, AUC? AUC from time zero to infinite time, AUCT AUC from zero to the time of the last
quantifiable concentration, AUCtau AUC during one dosing interval, C24 minimum observed concentration at the end of the dosing interval,
CLT/F apparent total body clearance, Cmax maximum observed concentration, CSP cyclosporine, CV coefficient of variation, DCV daclatasvir,
ND not determined, SD standard deviation, t half-life, TAC tacrolimus, Tmax time to reach Cmax
a Geometric mean (CV%)
b Median (minimum–maximum)
c Mean (SD)
Table 3 Statistical analyses of daclatasvir administered alone and in combination with either cyclosporine or tacrolimus
Treatment group Statistical comparison, GMR (90 % CI)
Cmax AUCT AUC? AUCtau C24
Group 1: CSP
CSP ? DCV versus CSP alone 0.96 (0.91–1.02) 1.02 (0.96–1.08) 1.03 (0.97–1.09) ND ND
DCV ? CSP versus DCV alone 1.04 (0.94–1.15) ND ND 1.40 (1.29–1.53) 1.56 (1.41–1.71)
Group 2: TAC
TAC ? DCV versus TAC alone 1.05 (0.90–1.23) 1.00 (0.87–1.15) 1.00 (0.88–1.13) ND ND
DCV ? TAC versus DCV alone 1.07 (1.02–1.12) ND ND 1.05 (1.03–1.07) 1.10 (1.03–1.19)
AUC area under the concentration–time curve, AUC? AUC from time zero to infinite time, AUCT AUC from time zero to the time of the last
quantifiable concentration, AUCtau AUC during one dosing interval, C24 minimum observed concentration at the end of the dosing interval,
CI confidence interval, Cmax maximum observed concentration, CSP cyclosporine, DCV daclatasvir, GMR geometric mean ratio,
ND not determined, TAC tacrolimus
286 M. Bifano et al.
(data not shown). The plasma concentration–time profiles
of multiple-dose daclatasvir in the presence and absence of
single-dose tacrolimus were comparable (Fig. 1d), and the
elimination phases were comparable. The multiple-dose
daclatasvir mean pharmacokinetic parameters were com-
parable when administered alone or concomitantly with
single-dose tacrolimus (Table 2), and measures of vari-
ability were also comparable. Concomitant single doses of
tacrolimus did not significantly affect the multiple-dose
pharmacokinetics of daclatasvir; the 90 % CIs of the
GMRs of Cmax, AUCtau and C24 of daclatasvir when con-
comitantly administered with tacrolimus versus adminis-
tration alone (Table 3) were contained entirely within the
accepted boundaries of equivalence.
3.4 Safety of Cyclosporine or Tacrolimus
Administered Alone or in Combination
with Daclatasvir
There were no serious AEs or AEs leading to discontin-
uation; all AEs were considered to be of mild intensity and
resolved prior to the end of the study, without sequelae. A
total of 21 subjects (75.0 %) reported 69 AEs, of which
58 AEs experienced by 20 subjects were considered related
to treatment.
In group 1, 13 of 14 subjects (92.9 %) reported 47 AEs,
of which 45 AEs were considered to be related to treat-
ment; more subjects experienced treatment-related AEs
during treatment with cyclosporine alone (8 subjects,
14 AEs) or in combination with daclatasvir (8 subjects,
16 AEs) than with daclatasvir alone (5 subjects, 15 AEs).
Treatment-related AEs in C2 subjects were diarrhoea,
nausea, headache, sinus congestion and feeling hot
(Table 4). Nine of 14 subjects in group 1 reported 13 AEs
of feeling hot after treatment including cyclosporine, but
none did during treatment with daclatasvir alone; the AEs
of feeling hot were not associated with clinically significant
elevations in body temperature. The AEs were comparable
to those generally observed in patients receiving cy-
closporine [13].
In group 2, 8 of 14 subjects (57.1 %) reported 22 AEs,
of which 13 AEs were considered to be related to
treatment; an equal number (n = 3) of subjects experi-
enced treatment-related AEs during each phase of treat-
ment in this group (tacrolimus alone, n = 3 AEs;
daclatasvir alone, n = 5 AEs; tacrolimus ? daclatasvir,
n = 5 AEs). The treatment-related AEs occurring in
C2 subjects in group 2 were headache, nausea and con-
stipation (Table 4).
4 Discussion
The objective of this study was to assess the effects of
multiple doses of daclatasvir on the single-dose pharma-
cokinetics of cyclosporine or tacrolimus, and the effects of
a single dose of either cyclosporine or tacrolimus on the
multiple-dose pharmacokinetics of daclatasvir in healthy
subjects.
Shared metabolic and distribution pathways often form
the basis of DDIs, and substrates and/or inhibitors of
CYP3A4 and P-gp are particularly susceptible to such in-
teractions. On the basis that daclatasvir is a substrate of
CYP3A4 [19] and a moderate inhibitor of P-gp, cy-
closporine is a substrate and inhibitor of both CYP3A4 and
P-gp [12, 13], and tacrolimus is a substrate of both
CYP3A4 and P-gp [12, 26], it was anticipated that co-
administration of daclatasvir with cyclosporine or tacroli-
mus would not affect the systemic exposures to either cy-
closporine or tacrolimus; it was also expected that while
tacrolimus would not affect the systemic exposure to da-
clatasvir, cyclosporine might do so.
The results of this study support these expectations. There
was no effect of concomitant multiple doses of daclatasvir on
the single-dose exposure to either cyclosporine or tacroli-
mus. These results suggest that weak-to-moderate inhibition
of P-gp by daclatasvir has minimal impacts on the absorp-
tion, disposition and excretion of cyclosporine and tacroli-
mus in vivo. Although a concomitant single dose of
tacrolimus did not affect the multiple-dose exposure to da-
clatasvir, concomitant administration of a single dose of
cyclosporine with multiple doses of daclatasvir resulted in
increases in the systemic exposure (AUC) and trough con-
centration (C24) of daclatasvir; Cmax was unaffected. The
Table 4 Treatment-related
adverse events occurring in





Preferred term, n (%) Group 1 treatment phase Group 2 treatment phase
CSP DCV CSP ? DCV TAC DCV TAC ? DCV
Feeling hot 6 (42.9) 0 7 (50.0) 0 0 0
Headache 3 (21.4) 3 (21.4) 1 (7.1) 0 2 (14.3) 0
Diarrhoea 3 (21.4) 1 (7.1) 2 (14.3) 0 0 0
Nausea 1 (7.1) 0 3 (21.4) 0 1 (7.1) 1 (7.1)
Sinus congestion 0 2 (14.3) 0 0 0 0
Constipation 0 0 0 2 (14.3) 0 0
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increases in the daclatasvir AUC and C24 were not consid-
ered to be clinically meaningful, on the basis that no expo-
sure–safety relationship was observed during phase 3 dose
selection using pharmacokinetic data from multiple studies
(daclatasvir dose range 1–100 mg once daily and 30 mg
twice daily) [27]. Among the 694 patients in the population
pharmacokinetic model who were within the 4th quartile of
steady-state exposures, 13 % of patients had daclatasvir
exposures ([22,000 ngh/mL) approximately threefold
higher than those observed here, with no unique safety sig-
nals observed in this subgroup. Thus, the 40 % increase in
exposure observed in this study was well within the range of
exposure estimated from the population pharmacokinetic
assessment conducted in the phase 2/3 programme using the
same data. These data support the use of daclatasvir in
transplant recipients and are consistent with observations
that when a DDI is observed with daclatasvir, daclatasvir is
usually the victim and not the perpetrator of the DDI.
While the results of this study support the concomitant
use of daclatasvir with calcineurin inhibitors, it is impor-
tant to note that only single doses of cyclosporine and
tacrolimus were used in this study, to limit the potential for
prolonged immunosuppression in healthy subjects. How-
ever, the single doses of cyclosporine and tacrolimus used
in this study delivered exposures comparable to those ob-
served for the therapeutic ranges of these medications
[13, 26], and thus these study findings can be extrapolated
to the clinical setting of a cyclosporine or tacrolimus
multiple dosing scenario. Additionally, a high dose of cy-
closporine (400 mg) was used in this study to maximize the
probability that if cyclosporine impacted the pharmacoki-
netics of daclatasvir, such observations would be made.
The use of high doses of cyclosporine and tacrolimus in
this study contrasted with those used in the assessment of
DDIs with telaprevir [14]. During the assessment of DDIs
with telaprevir, in which a DDI was anticipated, single doses
of cyclosporine 100 and 10 mg were used during treatment
with cyclosporine alone and cyclosporine in addition to te-
laprevir, respectively; tacrolimus 2 and 0.5 mg were
similarly used. During this study, concomitant administra-
tion of telaprevir resulted in 4.6 and 70-fold increases in the
exposure to cyclosporine and tacrolimus, respectively,
which represented potentially fatal increases in cyclosporine
and tacrolimus exposure; approximately fivefold increases
in the t values of both cyclosporine and tacrolimus were
also observed, which indicates the potential for drug accu-
mulation in the clinical setting when multiple doses are used.
Furthermore, the degree of the interactions between te-
laprevir and cyclosporine or tacrolimus [14] were compa-
rable to those observed with human immunodeficiency virus
(HIV) protease inhibitors and cyclosporine or tacrolimus, co-
administration of which requires significant modifications to
both the dosing level and dosing interval of cyclosporine or
tacrolimus [28]. In the current study, which revealed no
clinically meaningful interactions, the concentrations of
cyclosporine and tacrolimus were 40 and 10-fold higher,
respectively, than those used by Garg et al. [14].
The use of daclatasvir in transplant recipients has also
been reported in two published case reports. Daclatasvir has
been used successfully in combination with sofosbuvir as
part of a direct-acting antiviral-only regimen without signs
of a significant DDI with tacrolimus in a transplant recipient
with severe recurrent cholestatic HCV [24], and in combi-
nation with peginterferon/ribavirin without signs of a sig-
nificant DDI with cyclosporine in a transplant recipient [25].
Furthermore, the ability to use daclatasvir without dose
adjustments in subjects with hepatic impairment [the un-
bound daclatasvir AUC values in subjects with Child–Pugh
class B (moderate) and class C (severe) hepatic impairment
were within 5 % of the unbound daclatasvir AUC values in
healthy subjects] [23] offers a simple treatment option for
patients approaching the need for liver transplantation
(where a rapid reduction in viral load is required) and for
patients who have received a liver transplant and require
further antiviral therapy. Both populations are considered
to have high unmet clinical needs.
5 Conclusion
The results of this study indicate that daclatasvir can be used
in conjunction with cyclosporine or tacrolimus in transplant
recipients, with dose modification unlikely to be required.
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